RIBOCICLIB (RIB) plus LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL

被引：0
|
作者：
Farhat, Fadi [6 ]
Martin, Miguel [7 ]
Campone, Mario [8 ]
Bachelot, Thomas [1 ]
Neven, Patrick [12 ]
Martinez Rodriguez, Jorge Luis [3 ,4 ]
Yusof, Mastura Md [11 ]
Papazisis, Konstantinos [5 ]
Ferreira, Ana [2 ]
Ankrah, Nii [9 ]
Wu, Jiwen [9 ]
Zhou, Katie [9 ]
De laurentiis, Michelino [10 ]
机构：
[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[2] CUF Porto Hosp, Inst CUF Oncol, Porto, Portugal
[3] Escuela Nacl Med, Monterrey, Nuevo Leon, Mexico
[4] Tecnol Monterrey, Monterrey, Nuevo Leon, Mexico
[5] Euromed Gen Clin, Dept Oncol, Thessaloniki, Greece
[6] Hammoud Hosp UMC, Hematol Oncol Div, Saida, Lebanon
[7] Hosp Gregorio Maranon, Dept Oncol, Madrid, Spain
[8] Inst Canc Res Western France ICO, Lyon, France
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Natl Canc Inst, Fdn Pascale, Naples, Italy
[11] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia
[12] Univ Hosp Leuven UZ Leuven, Dept Obstet Gynecol, Leuven, Belgium
来源：
BREAST | 2019年 / 48卷
关键词：
D O I：
10.1016/S0960-9776(19)30676-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO67
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [41] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib 1 letrozole in hormone receptor-positive (HR1), HER2-negative (HER2-) advanced breast cancer (ABC)
    Spazzapan, S.
    Conte, P.
    Simoncini, E.
    Campone, M.
    Miller, M.
    Sonke, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] First Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib plus letrozole HR+HER2-advanced breast cancer trial
    Ferrario, C.
    Warner, E.
    Califaretti, N.
    Joy, A. A.
    Chia, S.
    Wu, J.
    Zarate, J. P.
    Lakshmi, M.
    Perri, S. R.
    Haftchenary, S.
    Dent, S. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib plus letrozole HR+HER2-advanced breast cancer trial
    Califaretti, N.
    Ferrario, C.
    Warner, E.
    Joy, A. A.
    Chia, S. K. L.
    Wu, J.
    Zarate, J. P.
    Menon-Singh, L.
    Leite, R. A.
    Haftchenary, S.
    Perri, S. R.
    Dent, S. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S369 - S370
  • [44] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [45] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
    Omori, Y.
    Enatsu, S.
    Cai, Z.
    Ishiguro, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [46] Phase IIIb CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2-advanced breast cancer (ABC): Interim results from the UK cohort
    Ring, Alistair
    Crook, Timothy
    Tuthill, Mark
    Roylance, Rebecca
    McGoldrick, Trevor
    Chan, Stephen
    Lo'Monte, Helen
    Roberts, William
    CANCER RESEARCH, 2020, 80 (04)
  • [47] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
    Janni, Wolfgang
    Burris, Howard A.
    Blackwell, Kimberly L.
    Hart, Lowell L.
    Chan, Arlene
    Nusch, Arnd
    Burdaeva, Olga Nikolaevna
    Alba, Emilio
    Yardley, Denise A.
    Bachelot, Thomas Denis
    Gil, Miguel J. Gil
    Richards, Donald A.
    Sparano, Joseph A.
    Kattan, Joseph Gergi
    Bourgeois, Hugues Pierre
    El Karak, Fadi Rafic
    Ramaswamy, Bhuvaneswari
    Sutradhar, Santosh C.
    Miller, Michelle Kristine
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [49] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial
    Harbeck, N.
    Vazquez, R. Villanueva
    Tripathy, D.
    Lu, Y.
    De Laurentiis, M.
    Kuemmel, S.
    Taylor, D.
    Bardia, A.
    Hurvitz, S.
    Chow, L.
    Im, S.
    Franke, F.
    Hughes, G.
    Miller, M.
    Kong, O.
    Chandiwana, D.
    Colleoni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S3 - S3
  • [50] Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (RIB)
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Fasching, P. A.
    De Laurentiis, M.
    Im, S-A.
    Petrakova, K.
    Bianchi, G. V.
    Esteva, F. J.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Pivot, X.
    Sondhi, M.
    Wang, Y.
    Chakravartty, A.
    Rodriguez-Lorenc, K.
    Jerusalem, G.
    ANNALS OF ONCOLOGY, 2019, 30
12345